IlluminOss Medical, Inc. news

IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, today announced an expanded U.S. Food and Drug Administration (FDA 510k) clearance for its Photodynamic Bone Stabilization System. The new clearance allows IlluminOss to be used in femur and tibia fractures as supplemental fixation to FDA-cleared fracture fixation systems.

“Femur and tibia fractures can be challenging in aging patients where osteoporotic bone often lacks the st

IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received expanded U.S. Food and Drug Administration (FDA 510k) clearance for its Photodynamic Bone Stabilization System for treatment of fractures of the fibula.

The IlluminOss System is a minimally invasive approach for fracture repair and stabilization through a patient-specific intramedullary implant. The system utilizes a light-curable liquid monomer,

IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received expanded U.S. Food and Drug Administration (FDA 510k) clearance for its Photodynamic Bone Stabilization System for treatment of fractures of the pelvis, cla

HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition of a majority stake in IlluminOss Medical, Inc. ("IlluminOss" or the "Company").

IlluminOss offers a unique and disruptive technology for the orthopedic trauma market. The Company`s Photodynamic Bone Stabilization System is a minimally invasive approach for fracture repair and stabilization through a patient-specific intramedullary implant. The system

IlluminOss Medical, Inc., a privately held, commercialstage medical device company focused on minimally invasive orthopedic fracture repair, today announced the U.S. launch and commercial availability of the IlluminOss? Bone Stabilization System for use in skeletally mature patients in the treatment of traumatic and fragility fractures of the humerus, radius and ulna. IlluminOss recently obtained FDA clearance for these exciting new indications*, having been previously available solely for th

IlluminOss Medical, a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that the IlluminOss Photodynamic Bone Stabilization System has received additional clinical clearance and is now indicated by the U.S. Food and Drug Administration (FDA) for use in skeletally mature patients in the treatment of traumatic, fragility, pathological, and impending pathological fractures of the humerus, radius and ulna.

&ld

IlluminOss Medical, a privately held, commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received U.S. Food and Drug Administration (FDA) de novo clearance for the IlluminOss Bone Stabilization System for treatment of impending and actual pathological fractures of the humerus, radius and ulna from metastatic bone disease.

The IlluminOss System incorporates the use of a thin-walled PET balloon that is infused wi

IlluminOss Medical, a privately-held, commercial stage medical device company focused on minimally invasive orthopedic fracture repair, today announced that Richard Terek, M.D., presented the first preliminary data from its U.S. pivotal clinical trial at the recent Musculoskeletal Tumor Society (MSTS) Meeting in Detroit. The IlluminOss System is the world’s only system of its kind which supports the treatment of fractures using patient-specific bone conforming intramedullary implants.